Form D · Other Health Care

Curavit Clinical Research Corp

Scarsdale, NY · CIK 0001947723

Offering snapshot reported Sep 5, 2024 · SEC filing

Reported sold
$11.4M
Offering amount: $11.6M
Investors reported
30
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 28, 2022
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$5.71M$11.4MOct 13, 2022: $8,493,329.00Oct 13, 2022Mar 8, 2024: $10,116,574.00Mar 8, 2024Sep 5, 2024: $11,426,701.00Sep 5, 2024

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$10,116,574 → $11,426,701

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 5, 2024Amendment$11,426,701$1,310,127vs Mar 8, 202430SEC filing
Mar 8, 2024Amendment$10,116,574$1,623,245vs Oct 13, 202230SEC filing
Oct 13, 2022Initial$8,493,329No comparison26SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-461679

Source: Form D, filed Sep 5, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
David Hanaman Director
Jackie Kent Director
Nathanael Lentz Director
Rich Lester Director
Joel Morse Director, Executive

Issuer details

Industry: Other Health Care (See others in industry)

Address:
18 Larch Lane
Scarsdale, NY, 10583